News

Awards, honors and achievements for the month of July.

An overactive immune response in the brain may play a role in Dravet Syndrome, a rare and severe genetic epilepsy that typically begins in infancy, according to Weill Cornell Medicine researchers. 

A new way to measure comorbidity – when a patient suffers from multiple diseases or health conditions – can be used to accurately predict a patient’s risk of hospitalization and future healthcare costs across a population, Cornell researchers report.

Cornell University President Michael I. Kotlikoff and Dr. Robert A. Harrington, Stephen and Suzanne...

Dr. Imperato-McGinley, esteemed endocrinologist, looks back at her 50-year career as a pioneer in her field and leader of the translational research enterprise at Weill Cornell Medicine. 

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. 

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers. 

Weill Cornell Medicine investigators have developed a simple, three-dimensional microenvironment to generate functional sperm-like cells in mice, which led to the birth of live pups. The study represents a significant step toward creating viable male gametes entirely outside the human body.

An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. 

Weill Cornell Medicine has received a four-year, $1.5 million grant from New York’s Empire State Development to increase resources available through BioVenture eLab, the institution’s hub for biomedical entrepreneurship. 

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

Researchers at Weill Cornell Medicine and Birkbeck, University of London, have identified where a commonly used anesthetic binds to sodium ion channels, revealing a molecular mechanism that may explain how these drugs dampen communication between neurons. 

Building on the academic medical center’s long history of surgical excellence, Dr. Donahue will focus on developing multidisciplinary programs that align patient care, research and education while fostering collaboration and discovery across the two institutions.

Dr. Mukesh Kumar has been selected as a Collaborative Research Network (CRN) Discovery Fellow by Aligning Science Across Parkinson’s (ASAP).

The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 million for Weill Cornell Medicine researchers to study a new gene therapy for Alzheimer’s disease in people who have a high genetic risk of developing the condition. The research could garner nearly $14 million in total if prescribed milestones are reached for years three through five.

An artificial intelligence system that operates like a collaborative team of medical experts could accelerate clinical trial design, one of the most difficult steps in drug development, according to a new study by Weill Cornell Medicine investigators. 

A protein produced by gut immune cells orchestrates both immune protection against pathogens and immune tolerance of gut bacteria, according to a study led by Weill Cornell Medicine investigators.

An aging Baby Boomer generation and contracting nursing home supply will put unprecedented pressure on long-term nursing home services in the United States. 

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University.